Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 47

Results For "CHI"

5487 News Found

Apollo Children’s hospital saves new born with rare brain vascular malformation
Healthcare | August 18, 2021

Apollo Children’s hospital saves new born with rare brain vascular malformation

Seen in 1 in 3 million births, the malformation was detected at the antenatal stage during the mother's pregnancy


India should focus on pharma intermediates self-sufficiency : A column by Dr. K. Nagaiah,Chief Scientist & Head - Centre for Natural Product and Traditional Knowledge, CSIR-IICT, Hyderabad
interviews | August 17, 2021

India should focus on pharma intermediates self-sufficiency : A column by Dr. K. Nagaiah,Chief Scientist & Head - Centre for Natural Product and Traditional Knowledge, CSIR-IICT, Hyderabad

India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers


Orchid Pharma reports net loss of Rs 30.90 cr in Q1FY22
News | August 16, 2021

Orchid Pharma reports net loss of Rs 30.90 cr in Q1FY22

EPS for the period at Rs. (7.57)


Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
Biotech | August 11, 2021

Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China

The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial


AIkido updates on use of machine learning in drug development orogram
Digitisation | August 09, 2021

AIkido updates on use of machine learning in drug development orogram

The goal for the project is the identification and optimization of anti-viral compounds.


China NMPA approves phase II clinical trial of ASC40
Policy | August 09, 2021

China NMPA approves phase II clinical trial of ASC40

Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne


We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.


India Initiates anti dumping probe against import of ATS-8 from China
Policy | August 04, 2021

India Initiates anti dumping probe against import of ATS-8 from China

Arch Pharma Labs has filed the application


Lonza to expand API manufacturing facility in Nansha, China
News | June 28, 2021

Lonza to expand API manufacturing facility in Nansha, China

The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022


'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.
Interviews | June 10, 2021

'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.

In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview: